Novo Nordisk Shares Surge Again in Today's Trading
In the realm of pharmaceutical giants, Novo Nordisk continues to make strides, with a market cap of $208 billion and a gross margin of 83.94%. However, The Motley Fool's Stock Advisor analyst team has not included Novo Nordisk in their list of the 10 best stocks for investors to buy now.
Recently, Novo Nordisk's chief scientific officer, Martin Holst Lange, commented on the company's oral Wegovy treatment. The results are promising, with one patient in three managing to lose more than 20% of their body weight. In the oral study, Novo Nordisk administered once-a-day doses of Wegovy in pill form over 64 weeks at a strength of 25 mg. The higher dosages helped patients lose an average of 16.6% of their body weight.
Despite these encouraging numbers, it's worth noting that when ingested instead of injected, much higher doses of semaglutide are required to get the same effect as in an injection. This could potentially pose challenges in the development and dosing of the oral Wegovy pill.
Eli Lilly, another pharmaceutical company, intends to develop a pill form of Wegovy that will exceed the previous injection doses by a large multiple in the future. This could potentially level the playing field and make the oral treatment more competitive.
Meanwhile, in the world of stock market investments, two stocks previously recommended by Stock Advisor have yielded significant returns. If an investor had invested $1,000 when Netflix was recommended on December 17, 2004, they would have $662,520 now. Similarly, an investment of $1,000 when Nvidia was recommended on April 15, 2005, would be worth $1,043,346 today. These figures demonstrate the market-crushing outperformance of Stock Advisor, with a total average return of 1,056%, compared to 188% for the S&P 500.
As of September 15, 2025, Novo Nordisk's stock is up 6.5%, with a current price of $61.90. The company's dividend yield stands at 2.79%.
While Novo Nordisk's oral Wegovy treatment shows promise, it remains to be seen whether it will be a game-changer in the pharmaceutical industry. For those interested in Stock Advisor's current top 10 stock picks, they are available when you join Stock Advisor. The stocks recommended by Stock Advisor could produce monster returns in the coming years.
Read also:
- Abu Dhabi initiative for comprehensive genetic screening, aiming to diagnose over 800 conditions and enhance the health of future generations in the UAE.
- Elderly shingles: Recognizing symptoms, potential problems, and available treatments
- Protecting Your Auditory Health: 6 Strategies to Minimize Noise Damage
- Exploring the Reasons, Purposes, and Enigmas of Hiccups: Delving into Their Origins, Roles, and Unsolved Aspects
